| Activation of RET as a Dominant Transforming Gene by Germline Mutations of MEN2A and MEN2B M Santoro, F Carlomagno, A Romano, DP Bottaro, NA Dathan, M Grieco, ... Science 267 (5196), 381-383, 1995 | 1016 | 1995 |
| ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases F Carlomagno, D Vitagliano, T Guida, F Ciardiello, G Tortora, G Vecchio, ... Cancer research 62 (24), 7284-7290, 2002 | 720 | 2002 |
| BAY 43-9006 inhibition of oncogenic RET mutants F Carlomagno, S Anaganti, T Guida, G Salvatore, G Troncone, ... Journal of the National Cancer Institute 98 (5), 326-334, 2006 | 577 | 2006 |
| Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. M Santoro, F Carlomagno, ID Hay, MA Herrmann, M Grieco, R Melillo, ... The Journal of clinical investigation 89 (5), 1517-1522, 1992 | 479 | 1992 |
| Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor … F Ciardiello, R Caputo, V Damiano, R Caputo, T Troiani, D Vitagliano, ... Clinical Cancer Research 9 (4), 1546-1556, 2003 | 460 | 2003 |
| RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. G Tallini, M Santoro, M Helie, F Carlomagno, G Salvatore, G Chiappetta, ... Clinical cancer research: an official journal of the American Association …, 1998 | 395 | 1998 |
| Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors F Carlomagno, T Guida, S Anaganti, G Vecchio, A Fusco, AJ Ryan, ... Oncogene 23 (36), 6056-6063, 2004 | 287 | 2004 |
| New therapeutic approaches to treat medullary thyroid carcinoma M Schlumberger, F Carlomagno, E Baudin, JM Bidart, M Santoro Nature clinical practice Endocrinology & metabolism 4 (1), 22-32, 2008 | 230 | 2008 |
| Minireview: RET: normal and abnormal functions M Santoro, RM Melillo, F Carlomagno, G Vecchio, A Fusco Endocrinology 145 (12), 5448-5451, 2004 | 228 | 2004 |
| The extent of linkage disequilibrium in four populations with distinct demographic histories AM Dunning, F Durocher, CS Healey, MD Teare, SE McBride, ... The American Journal of Human Genetics 67 (6), 1544-1554, 2000 | 225 | 2000 |
| NCOA4 deficiency impairs systemic iron homeostasis R Bellelli, G Federico, D Colecchia, A Iolascon, M Chiariello, M Santoro, ... Cell reports 14 (3), 411-421, 2016 | 222 | 2016 |
| Molecular mechanisms of RET activation in human cancer M Santoro, RM Melillo, F Carlomagno, A Fusco, G Vecchio Annals of the New York Academy of Sciences 963 (1), 116-121, 2002 | 219 | 2002 |
| BRAF is a therapeutic target in aggressive thyroid carcinoma G Salvatore, V De Falco, P Salerno, TC Nappi, S Pepe, G Troncone, ... Clinical Cancer Research 12 (5), 1623-1629, 2006 | 217 | 2006 |
| Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas MD Castellone, V Guarino, V De Falco, F Carlomagno, F Basolo, ... Oncogene 23 (35), 5958-5967, 2004 | 183 | 2004 |
| The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes F Carlomagno, D Vitagliano, T Guida, M Napolitano, G Vecchio, A Fusco, ... Cancer Research 62 (4), 1077-1082, 2002 | 170 | 2002 |
| Signalling of the Ret receptor tyrosine kinase through the c-Jun NH2-terminal protein kinases (JNKS): evidence for a divergence of the ERKs and JNKs pathways induced by Ret M Chiariello, R Visconti, F Carlomagno, RM Melillo, C Bucci, ... Oncogene 16 (19), 2435-2445, 1998 | 159 | 1998 |
| Molecular heterogeneity of RET loss of function in Hirschsprung's disease. F Carlomagno, G De Vita, MT Berlingieri, V De Franciscis, RM Melillo, ... The EMBO journal 15 (11), 2717-2725, 1996 | 156 | 1996 |
| Efficient Inhibition of RET/Papillary Thyroid Carcinoma Oncogenic Kinases by 4-Amino-5-(4-Chloro-Phenyl)-7-(t-Butyl)Pyrazolo[3,4-d]Pyrimidine (PP2) F Carlomagno, D Vitagliano, T Guida, F Basolo, MD Castellone, ... The Journal of Clinical Endocrinology & Metabolism 88 (4), 1897-1902, 2003 | 144 | 2003 |
| Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma F Basolo, R Giannini, C Monaco, RM Melillo, F Carlomagno, M Pancrazi, ... The American journal of pathology 160 (1), 247-254, 2002 | 143 | 2002 |
| Central role of RET in thyroid cancer M Santoro, F Carlomagno Cold Spring Harbor perspectives in biology 5 (12), a009233, 2013 | 133 | 2013 |
